[
  {
    "ts": null,
    "headline": "Biogen Receives European Commission Approval for High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy",
    "summary": "Approval is supported by data from the DEVOTE study which showed the benefit of the SPINRAZA 50 mg and 28 mg regimen in both treatment-naïve and previously-treated nusinersen patients with SMA1Biogen is dedicated to partnering with the SMA community to advance care through scientific innovation and a commitment to enhancing outcomes for people living with SMA CAMBRIDGE, Mass., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the European Commission (EC) has granted ma",
    "url": "https://finnhub.io/api/news?id=0cfedb8c827b8ee9abf471c1045e84a023e1fcc576fb8a975034468468b6f474",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768233900,
      "headline": "Biogen Receives European Commission Approval for High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy",
      "id": 138075403,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Approval is supported by data from the DEVOTE study which showed the benefit of the SPINRAZA 50 mg and 28 mg regimen in both treatment-naïve and previously-treated nusinersen patients with SMA1Biogen is dedicated to partnering with the SMA community to advance care through scientific innovation and a commitment to enhancing outcomes for people living with SMA CAMBRIDGE, Mass., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the European Commission (EC) has granted ma",
      "url": "https://finnhub.io/api/news?id=0cfedb8c827b8ee9abf471c1045e84a023e1fcc576fb8a975034468468b6f474"
    }
  },
  {
    "ts": null,
    "headline": "3 Reasons to Sell BIIB and 1 Stock to Buy Instead",
    "summary": "The past six months have been a windfall for Biogen’s shareholders. The company’s stock price has jumped 41.7%, setting a new 52-week high of $188.65 per share. This was partly thanks to its solid quarterly results, and the performance may have investors wondering how to approach the situation.",
    "url": "https://finnhub.io/api/news?id=f15fe0a0b4f1737ba2606bb36490a7fce84847a31dbcd2e541bb4a6f7e97af3d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768190718,
      "headline": "3 Reasons to Sell BIIB and 1 Stock to Buy Instead",
      "id": 138072524,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "The past six months have been a windfall for Biogen’s shareholders. The company’s stock price has jumped 41.7%, setting a new 52-week high of $188.65 per share. This was partly thanks to its solid quarterly results, and the performance may have investors wondering how to approach the situation.",
      "url": "https://finnhub.io/api/news?id=f15fe0a0b4f1737ba2606bb36490a7fce84847a31dbcd2e541bb4a6f7e97af3d"
    }
  }
]